FDA extends review of Tecentriq/Avastin combo for NSCLC

Roche (SIX:ROG; OTCQX:RHHBY) said FDA extended review for an sBLA for Tecentriq atezolizumab by three

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE